Johnson & Johnson unit Janssen Pharmaceuticals and Arcturus Therapeutics have agreed to collaborate on the research and development of RNA-based drugs for specific diseases using the latter's UNA Oligomer chemistry and LUNAR nanoparticle delivery technology. Under the terms of the agreement, Arcturus is entitled to receive an undisclosed upfront payment, research and development funding, milestone fees and sales royalties, while Janssen will shoulder development and commercialization costs related to the program.
Boehringer Ingelheim and Eli Lilly & Co. have launched an educational campaign for health care workers focused on sodium glucose co-transporters in support of empagliflozin, an SGLT2-inhibitor that the drugmakers developed. The campaign includes a website and a video.
The FDA approved Johnson & Johnson's Invokana, or canagliflozin, as an adjunct therapy to diet and exercise in adults with type 2 diabetes. The drug, from J&J unit Janssen Pharmaceuticals, is the first sodium-glucose co-transporter 2 inhibitor approved for diabetes. The approval was based on data from nine late-stage studies that showed improvements in hemoglobin A1c levels and fasting blood sugar levels.
The FDA approved Janssen Pharmaceuticals' Nucynta ER, or extended-release tapentadol, to treat pain tied to diabetic peripheral neuropathy in adults taking an opioid analgesic for an extended time. The approval "represents the ongoing commitment of Janssen to bring new and innovative products to patients and physicians for the management of pain," said Paul Chang, the company's vice president of medical affairs. The treatment is already approved for moderate to severe chronic pain.
Pharmacists and health care providers are being warned to be careful not to confuse an Alzheimer's disease drug for a diabetes pill. Janssen Pharmaceuticals Products said mix-ups between their drug, Reminyl, and the type 2 diabetes drug Amaryl, made by Aventis Pharmaceuticals, has resulted in at least two deaths.